Hdp Technescan (Sodium Oxidronate)

Hdp Technescan is primarily indicated for the management of elevated calcium levels associated with malignant disease.

• Treatment of hypercalcemia of malignancy when rapid reduction of serum calcium is required.
• Adjunct therapy for cancer patients with extensive bone metastases to limit calcium release.
• Supportive care in patients undergoing high‑dose chemotherapy who develop severe hypercalcemia.
• Prevention of skeletal complications in selected solid‑tumor or hematologic malignancies.
• Off‑label consideration for severe secondary hyperparathyroidism under specialist supervision.

Side effects of Hdp Technescan vary in frequency and severity.

Common

• Transient fever or chills during infusion.
• Nausea or vomiting shortly after administration.
• Mild, temporary hypocalcemia with associated tingling sensations.
• Headache or general fatigue.

Serious

• Acute renal impairment or failure.
• Severe, symptomatic hypocalcemia requiring medical intervention.
• Anaphylactic or severe hypersensitivity reactions.
• Osteonecrosis of the jaw, especially after prolonged use.
• Cardiac arrhythmias linked to electrolyte disturbances.

When prescribing or administering Hdp Technescan, several safety considerations are recommended.

• Assess renal function before each dose and monitor creatinine levels during therapy.
• Verify baseline serum calcium and vitamin D status; correct deficiencies prior to treatment.
• Avoid rapid infusion rates to reduce the risk of acute renal toxicity.
• Use caution in elderly patients or those with pre‑existing cardiovascular disease.
• Screen for a history of hypersensitivity to bisphosphonates or related compounds.
• Counsel patients on maintaining good oral hygiene and to report any jaw pain or lesions promptly.

Potential drug interactions with Hdp Technescan should be evaluated to minimize adverse outcomes.

Avoid

• Concurrent use of other nephrotoxic agents such as aminoglycosides or high‑dose NSAIDs.
• Simultaneous administration of additional bisphosphonate products.

Use with caution

• Calcium or vitamin D supplements that may alter serum calcium dynamics.
• Loop diuretics, which can affect renal handling of the drug.
• Corticosteroids or immunosuppressants that may increase infection risk.
• Anticoagulants, as changes in calcium levels can influence coagulation parameters.